细菌的氨基基酸酶和修饰的5-酸化合物:新的酶-原药对
Viktorija Preitakaitė1, Povilas Barasa2, Agota Aučynaitė1
1Department of Molecular Microbiology and Biotechnology, Institute of Biochemistry, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
PloS one
|November 30, 2023
概括
细菌的氨基基化酶YqfB和D8_RL可以激活新型前药. 这种酶-原药系统显示出基因导向的酶原药治疗的前景,降低了癌症细胞的活力.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 基因导向酶前药疗法 (GDEPT) 是一种创新的癌症治疗方法.
- 目前的GDEPT方法受到酶可用性和前药物设计的限制.
- 需要新的酶-原药系统来提高治疗疗效.
研究的目的:
- 为了评估细菌氨基基基酶YqfB和D8_RL对前药物激活的作用.
- 评估基于cytidine的新型前药在癌细胞中的疗效.
- 为了确定这些酶作为GDEPT剂的潜力.
主要方法:
- 已建立的癌细胞系稳定地表达YqfB或D8_RL.
- 合成并选择N4 - 乙化丁衍生物作为前药物.
- 在暴露于前药物时评估癌细胞活力.
主要成果:
- 细菌的氨基基化酶YqfB和D8_RL成功地激活了新型前药.
- 观察到HCT116结肠癌细胞活力的显著降低.
- 在工程细胞中证明了激活前药物的细胞毒性作用.
结论:
- 细菌YqfB和D8_RL氨基基基酶在激活基于cytidine的新型前体药物方面是有效的.
- 这种酶-原药组合显示出GDEPT应用的潜力.
- 该系统为向癌症治疗提供了一个有希望的新策略.
相关概念视频
Combined Effects of Drugs: Synergism
3.9K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.9K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Prodrugs
2.6K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.6K
Targets for Drug Action: Overview
6.3K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.3K
Aryldiazonium Salts to Azo Dyes: Diazo Coupling
2.9K
The reaction of weakly electrophilic aryldiazonium (also called arenediazonium) salts with highly activated aromatic compounds leads to the formation of products with an —N=N— link, called an azo linkage. This reaction, presented in Figure 1, is known as diazo coupling and occurs without the loss of the nitrogen atoms of the aryldiazonium salt. Highly activated aromatic compounds such as phenols or arylamines favor the diazo coupling reaction. The coupling generally occurs at the...
2.9K
Drug Metabolism: Phase II Reactions
3.8K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.8K


